

Asia Pacific Cancer Immunotherapy Market (2018 - 2024)

<https://marketpublishers.com/r/A52706F72BDEN.html>

Date: December 2018

Pages: 86

Price: US\$ 1,500.00 (Single User License)

ID: A52706F72BDEN

Abstracts

The Asia Pacific Market would witness market growth of 16.5% CAGR during the forecast period (2018 – 2024). Cancer immunotherapy is the type of cancer treatment helping the immune system fight cancer. There are various kinds of cancer immunotherapies used and they are monoclonal antibody, therapeutic cancer vaccines, checkpoint inhibitors, cytokines, and others. Growing patient population that is suffering from different types of cancer such as lung cancer, breast cancer, ovarian cancer, and other cancers are the factors that drive the global cancer immunotherapy market. Additionally, growing geriatric population and governmental contribution to healthcare expenditure are some other factors that add to the market growth.

Based on technology, the market is segmented into Monoclonal Antibodies, Cytokines & Immunomodulators and other technology. Based on application, the market is segmented into Lung cancer, Breast cancer, Colorectal, Prostate cancer, Head & Neck cancer and other application. Based on end user the market is segmented into Hospitals, Clinics and other end user. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca, Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Pfizer Inc., Bayer Ag, Immunomedics Inc., Novartis AG, F. Hoffmann-La Roche Ltd

Contents

CHAPTER 1. MARKET SCOPE & METHODOLOGY

- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
 - 1.4.1 Asia Pacific Cancer Immunotherapy Market, by Technology
 - 1.4.2 Asia Pacific Cancer Immunotherapy Market, by Application
 - 1.4.3 Asia Pacific Cancer Immunotherapy Market, by End User
 - 1.4.4 Asia Pacific Cancer Immunotherapy Market, by Countries
- 1.5 Methodology for the research

CHAPTER 2. MARKET OVERVIEW

- 2.1 Introduction
- 2.2 Key Factors Impacting the Market
 - 2.2.1 Market Drivers
 - 2.2.2 Market Restraints

CHAPTER 3. ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY

- 3.1.1 Asia Pacific Monoclonal Antibodies Cancer Immunotherapy Market by Country
- 3.1.2 Asia Pacific Cytokines & Immunomodulators Cancer Immunotherapy Market by Country
- 3.1.3 Asia Pacific Other Technology Cancer Immunotherapy Market by Country

CHAPTER 4. ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY APPLICATION

- 4.1.1 Asia Pacific Cancer Immunotherapy Lung Cancer Market by Country
- 4.1.2 Asia Pacific Cancer Immunotherapy Breast Cancer Market by Country
- 4.1.3 Asia Pacific Cancer Immunotherapy Colorectal Cancer Market by Country
- 4.1.4 Asia Pacific Cancer Immunotherapy Melanoma Market by Country
- 4.1.5 Asia Pacific Cancer Immunotherapy Prostate Cancer Market by Country
- 4.1.6 Asia Pacific Cancer Immunotherapy Head & Neck Cancer Market by Country
- 4.1.7 Asia Pacific Other Application Cancer Immunotherapy Market by Country

CHAPTER 5. ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY END USER

- 5.1.1 Asia Pacific Hospitals Cancer Immunotherapy Market by Country
- 5.1.2 Asia Pacific Clinics Cancer Immunotherapy Market by Country
- 5.1.3 Asia Pacific Other End User Cancer Immunotherapy Market by Country

CHAPTER 6. ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY COUNTRY

- 6.1 China Cancer Immunotherapy Market
 - 6.1.1 China Cancer Immunotherapy Market by Technology
 - 6.1.2 China Cancer Immunotherapy Market by Application
 - 6.1.3 China Cancer Immunotherapy Market by End User
- 6.2 Japan Cancer Immunotherapy Market
 - 6.2.1 Japan Cancer Immunotherapy Market by Technology
 - 6.2.2 Japan Cancer Immunotherapy Market by Application
 - 6.2.3 Japan Cancer Immunotherapy Market by End User
- 6.3 India Cancer Immunotherapy Market
 - 6.3.1 India Cancer Immunotherapy Market by Technology
 - 6.3.2 India Cancer Immunotherapy Market by Application
 - 6.3.3 India Cancer Immunotherapy Market by End User
- 6.4 South Korea Cancer Immunotherapy Market
 - 6.4.1 South Korea Cancer Immunotherapy Market by Technology
 - 6.4.2 South Korea Cancer Immunotherapy Market by Application
 - 6.4.3 South Korea Cancer Immunotherapy Market by End User
- 6.5 Singapore Cancer Immunotherapy Market
 - 6.5.1 Singapore Cancer Immunotherapy Market by Technology
 - 6.5.2 Singapore Cancer Immunotherapy Market by Application
 - 6.5.3 Singapore Cancer Immunotherapy Market by End User
- 6.6 Malaysia Cancer Immunotherapy Market
 - 6.6.1 Malaysia Cancer Immunotherapy Market by Technology
 - 6.6.2 Malaysia Cancer Immunotherapy Market by Application
 - 6.6.3 Malaysia Cancer Immunotherapy Market by End User
- 6.7 Rest of Asia Pacific Cancer Immunotherapy Market
 - 6.7.1 Rest of Asia Pacific Cancer Immunotherapy Market by Technology
 - 6.7.2 Rest of Asia Pacific Cancer Immunotherapy Market by Application
 - 6.7.3 Rest of Asia Pacific Cancer Immunotherapy Market by End User

CHAPTER 7. COMPANY PROFILES

- 7.1 Amgen Inc.
 - 7.1.1 Company Overview
 - 7.1.2 Financial Analysis
 - 7.1.3 Segmental & Regional Analysis
 - 7.1.4 Research and Development Expense
- 7.2 Merck & Company, Inc.
 - 7.2.1 Company Overview
 - 7.2.2 Financial Analysis
 - 7.2.3 Regional and Segmental Analysis
 - 7.2.4 Research & Development
- 7.3 Pfizer Inc.
 - 7.3.1 Company Overview
 - 7.3.2 Financial Analysis
 - 7.3.3 Segmental & Regional Analysis
 - 7.3.4 Revenue analysis by Region
 - 7.3.5 Research and Development
- 7.4 Immunomedics Inc.
 - 7.4.1 Company Overview
 - 7.4.2 Financial Analysis
 - 7.4.3 Revenue Analysis by Region
 - 7.4.4 Research and Development
- 7.5 Astrazeneca Plc.
 - 7.5.1 Company Overview
 - 7.5.2 Financial Analysis
 - 7.5.3 Segmental analysis
 - 7.5.4 Research & Development
- 7.6 F. Hoffmann-La Roche Ltd.
 - 7.6.1 Company Overview
 - 7.6.2 Financial Analysis
 - 7.6.3 Revenue & Segment analysis
 - 7.6.4 Research and Development
- 7.7 Eli Lilly and Company
 - 7.7.1 Company Overview
 - 7.7.2 Financial Analysis
 - 7.7.3 Segmental and Regional Analysis
 - 7.7.4 Research & Development Expense
- 7.8 Novartis AG
 - 7.8.1 Company Overview

7.8.2 Financial Analysis

7.8.3 Segmental and Regional Analysis

7.8.4 Research & Development Expense

7.9 Bristol-Myers Squibb Company

7.9.1 Company Overview

7.1 Bayer AG

7.10.1 Company Overview

7.10.2 Financial Analysis

7.10.3 Segmental and Regional Analysis

7.10.4 Research & Development Expense

List Of Tables

LIST OF TABLES

TABLE 1 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION

TABLE 2 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION

TABLE 3 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION

TABLE 4 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION

TABLE 5 ASIA PACIFIC MONOCLONAL ANTIBODIES CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION

TABLE 6 ASIA PACIFIC MONOCLONAL ANTIBODIES CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION

TABLE 7 ASIA PACIFIC CYTOKINES & IMMUNOMODULATORS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION

TABLE 8 ASIA PACIFIC CYTOKINES & IMMUNOMODULATORS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION

TABLE 9 ASIA PACIFIC OTHER TECHNOLOGY CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION

TABLE 10 ASIA PACIFIC OTHER TECHNOLOGY CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION

TABLE 11 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION

TABLE 12 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION

TABLE 13 ASIA PACIFIC CANCER IMMUNOTHERAPY LUNG CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION

TABLE 14 ASIA PACIFIC CANCER IMMUNOTHERAPY LUNG CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION

TABLE 15 ASIA PACIFIC CANCER IMMUNOTHERAPY BREAST CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION

TABLE 16 ASIA PACIFIC CANCER IMMUNOTHERAPY BREAST CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION

TABLE 17 ASIA PACIFIC CANCER IMMUNOTHERAPY COLORECTAL CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION

TABLE 18 ASIA PACIFIC CANCER IMMUNOTHERAPY COLORECTAL CANCER

MARKET BY COUNTRY, 2018 - 2024, USD MILLION

TABLE 19 ASIA PACIFIC CANCER IMMUNOTHERAPY MELANOMA MARKET BY COUNTRY, 2014 - 2017, USD MILLION

TABLE 20 ASIA PACIFIC CANCER IMMUNOTHERAPY MELANOMA MARKET BY COUNTRY, 2018 - 2024, USD MILLION

TABLE 21 ASIA PACIFIC CANCER IMMUNOTHERAPY PROSTATE CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION

TABLE 22 ASIA PACIFIC CANCER IMMUNOTHERAPY PROSTATE CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION

TABLE 23 ASIA PACIFIC CANCER IMMUNOTHERAPY HEAD & NECK CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION

TABLE 24 ASIA PACIFIC CANCER IMMUNOTHERAPY HEAD & NECK CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION

TABLE 25 ASIA PACIFIC OTHER APPLICATION CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION

TABLE 26 ASIA PACIFIC OTHER APPLICATION CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION

TABLE 27 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION

TABLE 28 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION

TABLE 29 ASIA PACIFIC HOSPITALS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION

TABLE 30 ASIA PACIFIC HOSPITALS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION

TABLE 31 ASIA PACIFIC CLINICS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION

TABLE 32 ASIA PACIFIC CLINICS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION

TABLE 33 ASIA PACIFIC OTHER END USER CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION

TABLE 34 ASIA PACIFIC OTHER END USER CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION

TABLE 35 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION

TABLE 36 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION

TABLE 37 CHINA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION

TABLE 38 CHINA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION

TABLE 39 CHINA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION

TABLE 40 CHINA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION

TABLE 41 CHINA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION

TABLE 42 CHINA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION

TABLE 43 CHINA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION

TABLE 44 CHINA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION

TABLE 45 JAPAN CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION

TABLE 46 JAPAN CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION

TABLE 47 JAPAN CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION

TABLE 48 JAPAN CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION

TABLE 49 JAPAN CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION

TABLE 50 JAPAN CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION

TABLE 51 JAPAN CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION

TABLE 52 JAPAN CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION

TABLE 53 INDIA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION

TABLE 54 INDIA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION

TABLE 55 INDIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION

TABLE 56 INDIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION

TABLE 57 INDIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION

TABLE 58 INDIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION

TABLE 59 INDIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017,

USD MILLION

TABLE 60 INDIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024,
USD MILLION

TABLE 61 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD
MILLION

TABLE 62 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD
MILLION

TABLE 63 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET BY
TECHNOLOGY, 2014 - 2017, USD MILLION

TABLE 64 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET BY
TECHNOLOGY, 2018 - 2024, USD MILLION

TABLE 65 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET BY
APPLICATION, 2014 - 2017, USD MILLION

TABLE 66 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET BY
APPLICATION, 2018 - 2024, USD MILLION

TABLE 67 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET BY END USER,
2014 - 2017, USD MILLION

TABLE 68 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET BY END USER,
2018 - 2024, USD MILLION

TABLE 69 SINGAPORE CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD
MILLION

TABLE 70 SINGAPORE CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD
MILLION

TABLE 71 SINGAPORE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY,
2014 - 2017, USD MILLION

TABLE 72 SINGAPORE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY,
2018 - 2024, USD MILLION

TABLE 73 SINGAPORE CANCER IMMUNOTHERAPY MARKET BY APPLICATION,
2014 - 2017, USD MILLION

TABLE 74 SINGAPORE CANCER IMMUNOTHERAPY MARKET BY APPLICATION,
2018 - 2024, USD MILLION

TABLE 75 SINGAPORE CANCER IMMUNOTHERAPY MARKET BY END USER, 2014
- 2017, USD MILLION

TABLE 76 SINGAPORE CANCER IMMUNOTHERAPY MARKET BY END USER, 2018
- 2024, USD MILLION

TABLE 77 MALAYSIA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD
MILLION

TABLE 78 MALAYSIA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD
MILLION

TABLE 79 MALAYSIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY,
2014 - 2017, USD MILLION

TABLE 80 MALAYSIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY,
2018 - 2024, USD MILLION

TABLE 81 MALAYSIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION,
2014 - 2017, USD MILLION

TABLE 82 MALAYSIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION,
2018 - 2024, USD MILLION

TABLE 83 MALAYSIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 -
2017, USD MILLION

TABLE 84 MALAYSIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 -
2024, USD MILLION

TABLE 85 REST OF ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, 2014 -
2017, USD MILLION

TABLE 86 REST OF ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, 2018 -
2024, USD MILLION

TABLE 87 REST OF ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY
TECHNOLOGY, 2014 - 2017, USD MILLION

TABLE 88 REST OF ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY
TECHNOLOGY, 2018 - 2024, USD MILLION

TABLE 89 REST OF ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY
APPLICATION, 2014 - 2017, USD MILLION

TABLE 90 REST OF ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY
APPLICATION, 2018 - 2024, USD MILLION

TABLE 91 REST OF ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY END
USER, 2014 - 2017, USD MILLION

TABLE 92 REST OF ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY END
USER, 2018 - 2024, USD MILLION

TABLE 93 KEY INFORMATION-AMGEN INC.

TABLE 94 KEY INFORMATION-MERCK & COMPANY INC.

TABLE 95 KEY INFORMATION- PFIZER INC.

TABLE 96 KEY INFORMATION- IMMUNOMEDICS INC.

TABLE 97 KEY INFORMATION- ASTRAZENECA PLC.

TABLE 98 KEY INFORMATION- F. HOFFMANN-LA ROCHE LTD.

TABLE 99 KEY INFORMATION – ELI LILLY AND COMPANY

TABLE 100 KEY INFORMATION – NOVARTIS AG

TABLE 101 KEY INFORMATION - BRISTOL-MYERS SQUIBB COMPANY

TABLE 102 KEY INFORMATION – BAYER AG

I would like to order

Product name: Asia Pacific Cancer Immunotherapy Market (2018 - 2024)

Product link: <https://marketpublishers.com/r/A52706F72BDEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A52706F72BDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970